Jeffrey Foy

Corporate Officer/Principal presso PEPGEN INC.

Health Technology

Consumer Services

Commercial Services

Profilo

Jeffrey Foy is a member of the Oligonucleotide Therapeutics Society, Inc. and the Vice President-Toxicology at PepGen Inc. He was previously an Executive Director-Toxicology at Dicerna Pharmaceuticals, Inc. He has a graduate degree from Northeastern University and an undergraduate degree from the University of Vermont.

Posizioni attive di Jeffrey Foy

Società	Posizione	Inizio
PEPGEN INC.	Corporate Officer/Principal	-
Oligonucleotide Therapeutics Society, Inc. Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators.	Corporate Officer/Principal	-

Tutte le posizioni attive di Jeffrey Foy

Precedenti posizioni note di Jeffrey Foy

Società	Posizione	Fine
DICERNA PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Jeffrey Foy

Formazione di Jeffrey Foy

Northeastern University	Graduate Degree
University of Vermont	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Jeffrey Foy

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
PEPGEN INC.	Health Technology

Aziende private	2
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.	Health Technology
Oligonucleotide Therapeutics Society, Inc. Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators.	Commercial Services